Han Yuan

Hanyuan Bio is a pioneering Chinese biotechnology company dedicated to developing next-generation gene editing technologies and transformative gene therapies. Founded by Dr. Yang Hui, a renowned expert in genome engineering, the company utilizes its proprietary CyDENT platform to enable high-precision base editing without the need for double-strand DNA breaks. This technology is designed to offer a safer and more efficient approach to treating a wide range of genetic disorders, including ophthalmic, metabolic, and neurological diseases. Hanyuan Bio's pipeline features several pre-clinical programs, such as treatments for Leber Congenital Amaurosis and Phenylketonuria, primarily delivered via Adeno-associated virus (AAV) vectors. Headquartered in Shanghai, the company has secured significant backing from top-tier venture capital firms to advance its mission of providing curative solutions for patients with unmet medical needs.